We are seeing some back-to-back tech IPOs this week, with cybersecurity firm Crowdstrike (NASDAQ: CRWD) getting an overwhelming response on Wednesday and freelancing platform Fiverr hitting the market on Thursday.
Closely following them is e-commerce firm Chewy, which sells pet food and other pet-related products. The company will start trading under the ticker symbol CHWY on the New York Stock Exchange on Friday.
The company had initially expected to price its 41.6 million shares in the range of $17 to $19, but considering the strong investor demand, raised it to $19 to $21. At the top end of this price range, the company would be valued at approximately $8.4 billion.
The company is eyeing $870 million in net proceeds from the IPO, which it says would be used for general corporate purposes.
The Dania Beach, Florida-based firm had recorded $3.5 billion in revenues last year, a 67% jump year-over-year. This is an increase from around $26 million in 2012. However, the company has not been profitable and recorded $267.9 million in 2018.
According to its SEC filing, for the quarter ended May 5, 2019, the company has projected revenues of $1.11 billion, a 45% increase from the same period last year, helped by customer growth. Chewy also said it expects to cut down its net losses to $29.5 million during this period, which is almost half of what it reported last year.
Founded in 2011, Chewy.com was acquired by retail chain PetSmart in 2017, reportedly for $3.35 billion. It was later spun off, but PetSmart continues to be a major stakeholder in the Chewy.
Chewy says it has over 45,000 products on is website from over 1,600 brands. Almost half of its revenues come from the sale of pet food, while the rest come from medicines and vet care products.
The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first half of 2021 compared to $168 billion for
The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in COVID care programs. Biotechnology giant
Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated